期刊文献+

注射用长效避孕给药系统研究进展 被引量:2

Research progress of injectable long-acting drug delivery systems for contraception
原文传递
导出
摘要 注射用长效避孕给药系统可维持避孕药恒定的血药浓度,精准控制药物持续释放几周甚至数月,从而大幅度减少给药次数,能较好解决目前临床上其他避孕制剂的续用率和依从性问题,为育龄女性提供一种相对安全、高效和简便的避孕方式。但目前相关上市产品有限,有待进一步开发新产品以满足各种避孕需求。按不同给药系统,长效避孕注射剂可分为油溶液、微晶混悬剂、微球和原位凝胶4类。经系统的文献调研,本文对各给药系统在避孕方面的研究进展作一综述,包括它们在研发阶段和临床应用中的特点,并总结归纳出开发长效避孕注射剂所面临的挑战。 Injectable long-acting drug delivery systems( DDS) for contraception can achieve several advantages:( 1) to maintain a constant drug concentration in the blood circulation;( 2) to provide an opportunity to control a precise drug release rate for several weeks or even months;( 3) to improve patient compliance and continuation rate than other currently used contraceptive agents by decreasing invasive administration and dosing frequencies; and( 4) to provide a relatively safe,efficient and simple contraception method for women of childbearing age. However,currently available products are limited and need to be further developed to meet different requirements. According to the DDS,long-acting contraceptives for injection can be divided into four types,namely oil solution,microcrystalline suspension,microspheres and in situ gels. This article aimed at helping to understand the current progress by reviewing useful data and information,including the key points of technology and applications in the clinical and development phases. Finally,we listed the main challenges of developing the injectable long-acting DDS.
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第3期297-304,共8页 Chinese Journal of New Drugs
基金 美国国家健康国际组织(FHI 360)资助项目(0647.0007/996345) 国家"十二五国家科技支撑"计划(2012BAI31B02)
关键词 注射给药 长效避孕 油溶液 微晶混悬剂 微球 原位凝胶 injection administration long-acting contraceptives oil solution microcrystalline suspension microspheres in situ gels
  • 相关文献

参考文献55

  • 1BURGESS D J, CROMMELIN DJ, HUSSAIN AS,et al. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report[ J ]. AAPS Pharm Sci,2004, 6(1): E11.
  • 2BURGESS D J, HUSSAIN AS, INGALLINERA TS,et al. Assuring quality and performance of sustained and controlled release parenterals: workshop report [ J ]. AAPS Pharm Sci, 2002,4 ( 2 ) : E7.
  • 3SIEPMANN J, SIEPMANN F. Microparticles used as drug delivery systems [ J ]. Smart Colloi Mater Progr Colloi Polymer Sci, 2006,133 : 15 - 21.
  • 4United Nations Department of Economic and Social Affairs, Population Division. World Contraceptive Use [ EB/OL ]. (2012 - 09 -01). https://en, wikipedia, org/wiki/United_Nations_Department_of_Economic_and_Social_Affairs.
  • 5STANBACK J, SPIELER J, SHAH I, et al. Community-based health workers can safely and effectively administer injectable contraceptives: conclusions from a technical consultation [ J ]. Contraception, 2010,81 ( 3 ) : 181 - 184.
  • 6HALPERN V,STALTER RM,OWEN DH,et al. Towards the development of a longer-acting injectable contraceptive: past research and current trends [ J ]. Contraception, 2015, 92 ( 1 ) :3 - 9.
  • 7GARZA-FLORES J, HALL PE, PEREZ-PALACIOS G. Longacting hormonal contraceptives for women[ J ]. J Steroid Biochem Mol Biol,1991,40(4 -6) :697 -704.
  • 8CHUE P. Risperidone long-acting injection[ J ]. Expert Rev Neurother ,2003,3 (4) :435 - 446.
  • 9PACKHAEUSER CB, SCHNIEDERS J, OSTER CG, et al. In situ forming parenteral drug delivery systems: an overview [ J ]. Eur J Pharm Biopharm, 2004,58 (2) :445 - 455.
  • 10BECK LR, POPE VZ, TICE TR, et al. Long-acting injectable microsphere formulation for the parenteral administration of levonorgestrel [ J ]. Adv Contracept, 1985,1 ( 2 ) : 119 - 129.

同被引文献56

  • 1http ://www. who. int/mediacentre/factsheets/fs351/zh/.
  • 2TOWNSEND IW, SITRUK-WARE R, WILLIAMS K, et al. New strategies for providing hormonal contraception in developing countries[ J]. Contraception ,2011,83 (5) :405 - 409.
  • 3FINER LB, HENSHAW SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001 [J]. Perspect Sex Reprod Health ,2006,38 ( 2 ) :90 - 96.
  • 4FELDBLUM PJ,HANITRINIAINA O,LENDVAY A, et al. Per- formance of Sino-implant (11) in routine service delivery in Mad- agascar[ J]. Contraception, 2013, 88 ( 1 ) : 103 - 108.
  • 5LENDVAY A, OTIENO-MASABA R, AZMAT SK, et al. Effec- tiveness, safety and acceptability of Sino-implant (11) during the first year of use: results from Kenya and Pakistani J]. Contracep- tion, 2014,89 ( 3 ) : 197 - 203.
  • 6STE1NER M J, LOPEZ LM, GRIMES DA, et al. Sino-implant ( II)-a levonorgestrel-releasing two-rod implant : systematic re- view of the randomized controlled trials [ J ]. Contraception, 2010, 81(3) :197 -201.
  • 7GRAESSLIN O,KORVER T. The contraceptive efficacy of Impl- anon: a review of clinical trials and marketing experience [ J]. Eur J Contracept Reprod Health Care,2008,13 ( Suppl 1 ) :4 - 12.
  • 8MASSAI MR, DIAZ S, QUINTEROS E, et al. Contraceptive ef- ficacy and clinical performance of Nestorone implants in postpar- tum women[ Jl ~ Contraception, 2001,64(6) :369 - 376.
  • 9SIVIN I, CROXATTO H, BAHAMONDESL, etal. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women [ J ~. Contraception, 2004,69 (2) :137 -144.
  • 10COUTINHO EM, DE SOUZA ~C, ATHAYDE C, et al. Multi- center clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant[J]. Con- traception, 1996,53 (2) : 121 - 125.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部